4D Molecular Therapeutics FDMT 深 沪
已收盘 08-01 16:00:00 美东时间
6.42
+1.920
+42.67%
华盛通- 最 高6.69
- 今 开5.28
- 成交量 3163.07万股
- 最 低 4.99
- 昨 收 4.50
- 总市值 2.97亿
- 52周最高 17.41
- 市盈率 静 --
- 换手率 0.07%
- 52周最低 2.235
- 委 比 -86.20%
- 总股本 4632.46万
- 历史最高 55.11
- 量 比 46.46
- 振 幅 37.78%
- 历史最低 2.235
- 每 手 1
- 风险率 6.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Market-Moving News for August 1st
FIG: 28% | Figma shares are trading higher on momentum following Thursday's IPO. COIN: -11% | Coinbase shares are trading lower after the company reported worse-than-expected Q2 adjusted EPS and
08-01 19:15
Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Apple Inc. (NASDAQ:AAPL) rose in pre-market trading as the company po...
08-01 18:56
制药巨头扎堆做“减法”：20家药企7月宣布裁员
2025 年已经过半，裁员、削减成本，成为众多药企不得不面对的现实。据 Fierce Biotech 统计，仅在今年 7 月，就有 20 家药企宣布了裁员计划...
08-01 12:49
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 4D Molecular Therapeutics (NASDAQ:FDMT) shares moved upwards by 33.1% ...
08-01 05:07
4D Molecular Therapeutics shares are trading higher after the company announced results from its 4D-150 SPECTRA clinical trial.
4D Molecular Therapeutics shares are trading higher after the company announced...
08-01 05:03
4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update
4D-150在治疗糖尿病黄斑水肿（DME）的临床试验中表现出良好的耐受性、一致且持久的临床活性，以及剂量依赖性效果，显著减少了治疗负担。52周和60周的数据表明，接受Phase 3剂量（3E10 vg/eye）的患者在视敏度和解剖控制方面取得了持续改善。与标准治疗方案相比，治疗负担降低了78%。EMA与FDA一致，同意单一Phase 3临床试验的数据可用于4D-150在DME中的上市申请，提升了该疗法的前景。
07-31 20:05
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists
4D Molecular Therapeutics announced podium presentations at the 43rd Annual ASRS Meeting, focusing on interim results from the SPECTRA and PRISM Phase 2 clinical trials evaluating 4D-150 for Diabetic Macular Edema and Neovascular AMD, respectively. The SPECTRA trial includes 52-week primary endpoint and 60-week analysis data as of May 2, 2025, while the PRISM trial highlights 52-week results. Both trials aim to demonstrate the potential of 4D-150...
07-24 12:00
4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics授予新员工4,600个限制性股票单位，并介绍其正在开发治疗视网膜血管疾病和囊性纤维化的创新疗法。
07-11 20:05
Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Maintains $25 Price Target
Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and maintains $25 price target.
07-03 20:05
4D Molecular to layoff about 25% of workforce
4D Molecular Therapeutics (NASDAQ:FDMT) announced a significant workforce reduction of approximately 25% of its current and planned positions to streamline operations. The company is also speeding up ...
07-03 04:47
